Journal
IUBMB LIFE
Volume 61, Issue 7, Pages 723-730Publisher
WILEY
DOI: 10.1002/iub.198
Keywords
CDCP1; Src; integrin; cancer; leukemia
Categories
Funding
- Australian National Health and Medical Research Council [339732]
- National Institutes of Health [CA55852, CA105412]
Ask authors/readers for more resources
In the last few years dysregulated expression of the cell surface glycoprotein CUB domain-containing protein 1. (CDCP1) has been associated with several cancers and this cell surface molecule has been recognized both as a tumor marker and as a potential target to disrupt progression of cancer. Here we summarize what is known about CDCP1 including its structural features, expression in normal and cancerous tissues, and the in vitro experiments and studies in animal models that have provided the key insights into its potential role in tumor formation and metastasis in humans. We conclude by highlighting opportunities and challenges in targeting CDCP1 in cancer. (C) 2009 IUBMB IUBMB Life, 61(7): 723-730, 2009
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available